Hyderabad-based MSN Labs to make Covid-19 drug Baricitinib

MSN will launch the product under the brand name BARIDOZ in two strengths 2 mg and 4 mg.

Published: 14th May 2021 05:40 AM  |   Last Updated: 14th May 2021 05:40 AM   |  A+A A-

Pharmaceutical tablets and capsules are arranged on a table in a photo illustration

For representational purposes (File Photo | Reuters)

By Express News Service

HYDERABAD: Hyderabad-based MSN Labs, on Thursday, announced that it has entered into a royalty-free, non-exclusive voluntary licence agreement with Eli Lilly and Company of the US for manufacturing and marketing Covid-19 drug Baricitinib in India.

The drug, Baricitinib, has been granted a restricted use approval in India by the Central Drugs and Standard Control Organisation for emergency use in combination with Remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation or extra corporeal membrane oxygeneration, a release from the company said.

Dr MSN Reddy, CMD, MSN Group said: “This collaboration with Eli Lilly and Company is a milestone in India’s fight against Covid-19 and will help in increasing the availability and affordability of Baricitinib. MSN will launch the product under the brand name BARIDOZ in two strengths 2 mg and 4 mg.”

Now we are on Telegram too. Follow us for updates
India Matters

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

Videos
Gallery